Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor developed as a cure for liver fibrosis and cirrhosis, was evaluated to evaluate the result of hepatic impairment on its pharmacokinetics and protection to address regulatory necessities. Members ended up also excluded if they'd clinically important abnormalities in electrocardiogram (ECG) results https://selvigaltinoralsmallmolec58913.blogpixi.com/39591376/the-basic-principles-of-gb1211